A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

NCT03084796 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

733

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: CHF 5259
DRUG: Placebo
DRUG: Tiotropium Bromide 18 µg Inhalation Capsule

Sponsor

Chiesi Farmaceutici S.p.A.